Clinical trial
A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy
NCT05668741 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 27, 2023
- Completion date
- September 9, 2026
- Enrollment
- 26 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.